Gene therapy for pancreatic and biliary malignancies

Annals of Oncology

Volumn 10, Issue SUPPL. 4, 1999, Pages

  Aspinall, R J ^a   Lemoine, N R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Cholangiocarcinoma; DNA vaccination; Gene therapy; Immunotherapy; Pancreatic cancer; Prodrug activation; ras

Indexed keywords

VIRUS VECTOR;

ADENOVIRUS; BILIARY TRACT CANCER; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; DENDRITIC CELL; GENE REPRESSION; GENE THERAPY; HUMAN; ONCOGENE K RAS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; SUICIDE GENE; TUMOR SUPPRESSOR GENE;

EID: 0032784777     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_4.S188     Document Type: Conference Paper

References (76)

1. Lemoine NR. Molecular advances in pancreatic cancer. Digest. 1997; 58: 550-6.
2. Hahn SA, Schmiegel WH. Recent discoveries in cancer genetics of exocrine pancreatic neoplasia. Digestion 1998; 59: 493-501.
3. Longnecker DS, Terhune PG. What is the true rate of K-ras mutation in carcinoma of the pancreas? Pancreas 1999; 17: 323-4.
4. Goggins M, Schutte M, Lu J, et al Germline BRCA2 mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996; 56: 3808-13.
5. Hahn SA, Seymour AB, Hoque ATMS, et al Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res 1995; 55: 4670-5.
6. Korc M. Rule of polypeptide growth factors and their receptors in human pancreatic cancer. In: Reber H (ed) Pancreatic Cancer. Humana Press, New Jersey 1998.
7. Alison MR, Golding M, Sarraf CE. Liver stem cells: when the going gets tough they get going. Int J Exp Path 1997; 78: 365-81.
8. Thorgeirsson SS, Evarts RP, Bisgaard HC, et al Hepatic stem cell compartment: activation and lineage commitment. Proc Soc Exp Biol Med 1993; 204: 253-60.
9. Shinagawa T, Tadokoro M, Maeyama S, et al Alpha fetoprotein-producing acinar cell carcinoma of the pancreas showing multiple lines of differentiation. Virchows Arch 1995; 426: 419-23.
10. Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the extrahepatic bile ducts: histologic types, stage of disease, grade and survival rates. Cancer 1992; 70: 1498-1501.
11. Levi S, Urbano-Ispizua A, Gill R, et al Multiple K-ras codon mututions in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res 1991; 51: 3497-502.
12. Kiba T, Tsuda H, Pairojkul C, et al Mutations of the p53 suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand. Molec Carcinog 1993; 8: 312-8.
13. Ohashi K, Tsutsumi M, Nakajima Y, et al Ki-ras point mutations and proliferative activity in biliary tract carcinomas. Brit J Cancer 1996; 74: 930-5.
14. Celli A, Que FG. Dysregulation of apoptosis in the cholangiopathies and cholangiocarcinoma. Semin Liver Dis 1998; 18: 177-85.
15. Fujiwara T, Cai DW, Georges RN, et al Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994; 86: 1458-62.
16. Zhang WW, Fang X, Mazur W, et al High-efficiency gene transfer and high-level expression of wild-lype p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1994; 1: 5-13.
17. Liu TJ, Zhang WW, Taylor DL, et al Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 1994; 54: 3662-7.
18. Bouvet M, Bold RJ, Lee J, et al Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann Surg Oncol 1998; 5: 681-688.
19. Fujiwara T, Grimm EA, Mukhopadhyay T, et al Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994; 54: 2287-91.
20. Heise C, Sampson-Joannes A, Williams A, et al ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumor efficacy that can be augmented by standard chemotherapeutic agents. Nature Med 1997; 3: 639-45.
21. Kirn D, Hermiston T, McCormick F. ONYX-015: Clinical data are encouraging. Nature Med 1998; 4: 1341-2.
22. WAFI recombinant adenovirus. Pancr 1998; 16: 107-13.
23. Jin X, Nguyen D, Zhang WW, et al Cell cycle arrest and inhibition of tumour cell proliferation by the p16 INK4 gene mediated by adenovirus vector. Cancer Res 1995; 55: 3250-3.
24. Sandig V, Brand K, Herwig S, et al Adenovirally-transfected p16 INK4/CDKN2 and p53 genes co-operate to induce apoptotic tumor cell death. Nature Med 1997; 3: 313-9.
25. Terao R, Honda K, Hatano E, et al Suppression of proliferative cholangitis in a rat model with direct adenovirus-mediated retinoblastoma gene transfer to the biliary tract. Hepalology 1998; 28: 605-12.
26. Sato T, Yamauchi N, Sasaki H, et al An apoptosis-inducing gene therapy for pancreatic cancer with a combination of 55-kDa tumor necrosis factor (TNF) receptor gene transfection and mutein TNF administration. Cancer Res 1998; 58: 1677-83.
27. Kawaguchi Y, Takebayashi H, Kakizuka A, et al Expression of Fas-estrogen receptor fusion protein induces cell death in pancreatic cancer cell lines. Cancer Lett 1997; 116: 53-9.
28. Georges RN, Mukhopadhyay, Zhung Y, et al Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res 1993; 53: 1743-6.
29. Aoki K, Yoshida T, Sugimura T, Terada M. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumour dissemination in the murine peritoneal cavity. Cancer Res 1995; 55: 3810-6.
30. Cai DW, Mukhopadyay T, Roth JA. Suppression of lung cancer cell growth by ribozyme-mediated modification of p53 pre-mRNA. Cancer Gene Ther 1995; 2: 199-205.
31. Colomer R, Lupu R, Bacus SS, Gelmann EP. ErbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br J Cancer 1994; 70: 819-25.
32. Harnois DM, Que FG, Celli A, et al Bcl-2 is overexpressed and allers the threshold for apoptosis in a cholangiocarcinoma cell line. Hepatology 1997; 26: 884-90.
33. Barton CM, Lemoine NR, Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression. Br J Cancer 1995; 71: 429-37.
34. Klinman DM, Yamshehikov G, Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 1997; 179: 97-106.
35. Han X, Kasahara N, Kan YW. Ligand-directed retroviral targeting of human breast cancer cells. Proc Natl Acad Sci USA 1995; 92: 9747-51.
36. Mohr L, Schauer JI, Boulin RH, et al Targeted gene transfer to hepatocellular carcinoma cells in vitro using a novel monoclonal antibody-based gene delivery system. Hepatology 1999; 29: 82-9.
37. Dematteo RP, McClane SJ, Fisher K, et al Engineering tissue-specific expression of a recombinant adenovirus: selective transgene transcription in the pancreas using the amylase promoter. J Surg Res 1997; 72: 155-61.
38. Osaki T, Tanio Y, Tachibana I, et al Gene therapy for carcinoembryonic antigen-producing lung cancer cells by cell type specific expression of herpes simplex virus thymidine kinase gene. Cancer Res 1994; 54: 5258-61.
39. Ring CJA, Martin LA, Blouin P, et al Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes to drive tumor-selective expression of a prodrug-activating enzyme. Gene Ther 1997; 4: 1045-52.
40. Sasaki M, Nakanuma Y. Expression of mucin core protein of mammary type in primary liver cancer. Hepatology 1994; 20: 1192-7.
41. Balague C, Gambus G, Carrato C, et al Altered expression of MUC2, MUC4 and MUC5 mucin genes in pancreas tissues and cancer cell lines. Gastroenterology 1994; 106: 1054-61.
42. Terada T, Ohta T, Sasaki M, et al Expression of MUC apomucins in normal pancreas and pancreatic tumours. J Pathol 1996; 180: 160-5.
43. Sikora K, Harris J, Hurst H, Lemoine NR. Therapeutic strategies using c-erbB-2 promoter-controlled drug activation. Ann NY Acad Sci 1994; 716: 115-24.
44. Ring CJA, Harris JD, Hurst HC, Lemoine NR. Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter. Gene Ther 1996; 3: 1094-103.
45. Pandha H, Rigg A, Martin LA, et al Genetic prodrug activation therapy for breast cancer targeted by the ERBB2 promoter: results of a phase I study. J Clin Oncol (in press).
46. Freeman SM, Abboud CN, Whartenby KA, et al The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-83.
47. Yang L, Chiang Y, Lenz HJ, et al Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase / ganciclovir-based gene therapy of human gastrointestinal tumor cells. Hum Gene Ther 1998; 9: 719-28.
48. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970; 13: 1-27.
49. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol 1996; 8: 271-80.
50. Matzinger P. An innate sense of danger. Semin Immunol 1998: 10: 399-415.
51. Melcher A, Todryk S, Hardwick N, et al Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nature Med 1998; 5: 581-7.
52. Vermorken J, Claessen A, van Tinteren H, Gall H, et al Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999; 353: 345-50.
53. Rosenberg SA. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Annu Rev Med 1996; 47: 481-91.
54. Bohm CM, Hanski ML, Stefanovic S, et al Identification of HLA-A2-restricted epitopes of the tumor-associated antigen MUC2 recognized by human cytotoxic T cells. Int J Cancer 1998; 75: 688-93.
55. McCarty TM, Liu X, Sun JY, et al Targeting p53 for adoptive T-cell immunotherapy. Cancer Res 1998; 58: 2601-5.
56. Fenton RG, Taub DD, Kwak LW, et al Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J Natl Cancer Inst 1993; 85: 1294-302.
57. Peace DJ, Smith JW, Chen W, et al Lysis of Ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitru immunisation with mutated Ras peptide. J Exp Med 1994; 179: 473-9.
58. Gjertsen MK, Saeterdal I, Thorsby E, et al Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination. Br J Cancer 1996; 74: 1828-33.
59. Rosenberg S, Packard B, Aebersold P. Use of tumor infiltrating lymphocytes and IL-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988; 319: 1676-9.
60. Simons JW, Jaffee EM, Weber C, et al Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex-vivo granulocyte-macrophagecolony-stimulating factor gene transfer. Cancer Res 1997; 57: 1537-46.
61. Jaffee EM, Abrams R, Cameron J, et al Clinical protocol: a phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. Hum Gene Ther 1998; 9: 1951-71.
62. Dohring C, Angman L, Spagnoli G, Lanzavecchia A. T-helper and accessory-cell independent cytotoxic responses to human tumor cells transfected with a B7 retorviral vector. Int J Cancer 1994; 57: 754-9.
63. Chen C-H, Wu T-C. Experimental vaccine strategies for cancer immunotherapy. J Biomed Sci 1998; 5: 231-52.
64. Cohen AD, Boyer JD, Weiner DB. Modulating the immune response to genetic immunization. FASEB J 1998; 12: 1611-26.
65. Timmerman JT, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999; 50: 507-29.
66. Zilvogel L, Regnault A, Lozier A, et al Eradication of established murine tumours using a novel cell-free vaccine: dendritic cell-derived exosomes. Nature Med 1998; 4: 594-600.
67. Pederson LC, Buchsbaum DJ, Vickers SM, et al Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Res 1997; 57: 4315-32.
68. Freytag SO, Rogulski KR, Paielli DL, et al A novel three-pronged approach to kill cancer cells selectively: concomitanl viral, double suicide gene and radiotherapy. Hum Gene Ther 1998; 9: 1323-33.
69. Dellabona P, Moro M, Crosti MC, et al Vascular attack and immunotherapy: a 'two hits' approach to improve biological treatment of cancer. Gene Ther 1999; 6: 153-4.
70. McClane SJ, Chirmule N, Burke CV, Raper SE. Characterization of the immune response after local delivery of recombinant adenovirus in murine pancreas and successful strategies for readministration. Hum Gene Ther 1997; 8: 2207-16.
71. Ilan Y, Sauter B, Chowdhury NR, et al Oraltolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses. Hepatology 1998; 27: 1368-76.
72. McClane SJ, Hamilton TE, Burke CV et al Functional consequences of adenovirus-mediated murine pancreatic gene transfer. Hum Gene Ther 1997; 8: 739-46.
73. Schmid RM, Weidenbach H, Yamagushi H, et al Direct gene transfer into the rat pancreas using DNA-liposomes. Eur J Clin Invest 1998; 28: 220-6.
74. Denham W, Denham D, Yang J, et al Transient human gene therapy: a novel cytokine regulatory strategy for experimental pancreatitis. Ann Surg 1998; 227: 812-20.
75. Kanai F, Kawakami T, Hamada H, et al Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res 1998; 58: 1946-51.
76. Chen Y. Inhibition of K-ras-transformed rodent and human cancer cell growth via induction of apoptosis by irreversible inhibitors of ras endoprotease. Cancer Lett 1998; 131: 191-200.